Insmed (INSM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
19 May, 2026Opening remarks and agenda
Meeting called to order at 9:00 AM ET on May 13, 2026, with all board members present and introductions made.
Virtual format adopted to increase inclusivity and shareholder participation.
Agenda and rules of conduct posted online, with instructions for submitting questions.
Board and executive committee updates
David McGirr not standing for re-election; appreciation expressed for his service.
Introduction of board members and executive officers in attendance.
Corporate governance
Notice of meeting and proxy materials distributed to shareholders of record as of March 6, 2026.
Inspector of election appointed and sworn in; procedures for vote counting and record-keeping outlined.
Shareholder list available for inspection during the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Insmed
- BRINSUPRI’s stellar launch and pipeline advances set the stage for multi-year growth.INSM
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - 44% growth and high patient retention drive confidence in $1B+ revenue and future expansion.INSM
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - Strong Q1 2026 growth and clinical advances drive expansion in respiratory and rare disease markets.INSM
Investor presentation20 May 2026 - Strong launch momentum and pipeline advances set the stage for robust future growth.INSM
Bank of America Global Healthcare Conference 202612 May 2026 - Q1 2026 revenues soared 230% to $306M, driven by BRINSUPRI and ARIKAYCE growth.INSM
Q1 20267 May 2026 - Record 2025 revenues, major product approvals, and strong governance set the stage for continued growth.INSM
Proxy filing1 Apr 2026 - Votes will be cast on director elections, executive pay, and auditor ratification for 2026.INSM
Proxy filing1 Apr 2026 - Late-stage pipeline and strong launches position for major growth and label expansions.INSM
Investor presentation25 Mar 2026 - ARIKAYCE improved symptoms and culture conversion, supporting label expansion in MAC lung disease.INSM
Study result23 Mar 2026